Disease · EFO_1001350

Immunoblastic Lymphadenopathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Immunoblastic Lymphadenopathy. Diseases, record EFO_1001350. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001350

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Immunoblastic Lymphadenopathy; Open Targets
Open Targets ID: EFO_1001350; Open Targets
Other names: AILD, AILT, T-cell lymphoma, AILD type, angioimmunoblastic T-cell lymphoma, angioimmunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy type T-cell lymphoma, angioimmunoblastic lymphadenopathy with Dysproteinemia, lymphogranulomatosis X; Open Targets
MeSH: D007119; MeSH
Highest stage of its drugs: Phase 3, for 5 of its 42 drugs, from ClinicalTrials.gov; Open Targets

Drugs42

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
AZACITIDINE	CHEMBL1489	Small molecule	Phase 3	ClinicalTrials.gov	6	6	5	Drugs and targets
ROMIDEPSIN	CHEMBL343448	Protein	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BENDAMUSTINE	CHEMBL487253	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GOLIDOCITINIB	CHEMBL4577523	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ZANOLIMUMAB	CHEMBL2108063	Antibody	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	9	9	9	Drugs and targets
TUCIDINOSTAT	CHEMBL3621988	Small molecule	Phase 2	ClinicalTrials.gov	9	9	9	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets

1 to 10 of 42

See all 42 drugs

Targets110

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	4	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 110

See all 110 targets

Trials45

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05011058	An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas	Phase 2	102	2025-07-28	Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder	NANATINOSTAT, VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT03703375	Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma	Phase 3	93	2024-07-08	Lymphoma, T-Cell	AZACITIDINE, GEMCITABINE, ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Phase 2	77	2022-05-04	Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory, Peripheral T-cell Lymphoma NOS, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma Refractory, Anaplastic Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, ALK-negative Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, Cutaneous T-cell Lymphoma	TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03397706	Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies	Phase 1/2	64	2025-03-20	Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders	NANATINOSTAT, VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00655668	A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma	Phase 2	54	2012-01-05	T-cell Non-Hodgkin's Lymphoma	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02561273	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma	Phase 1/2	54	2021-06-18	Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, LENALIDOMIDE, PREDNISONE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT02232516	Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma	Phase 2	30	2024-04-10	Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome	LENALIDOMIDE, ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT02273739	Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation	Phase 1/2	21	2021-02-23	Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma, Chondrosarcoma	ENASIDENIB	Its record names the disease	ClinicalTrials.gov
NCT03070964	A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma	Phase 2	14	2020-10-14	Lymphoma	PLITIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT01561833	A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients	Phase 1	12	2020-08-13	T Cell Lymphoma	SORAFENIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 45

See all 45 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Treatment (10 mg Lenalidomide) vs Treatment (15 mg Lenalidomide): deaths from any cause	9 of 39	1 of 4	43	NCT02561273	Trial comparisons
Treatment (10 mg Lenalidomide) vs Treatment (15 mg Lenalidomide): serious adverse events	14 of 39	2 of 4	43	NCT02561273	Trial comparisons

Papers from its trials21

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31123029	RESULT	1	PubMed
30694529	RESULT	1	PubMed
29072976	RESULT	1	PubMed
28516671	RESULT	1	PubMed
25482745	RESULT	1	PubMed
25113753	RESULT	1	PubMed
23731832	RESULT	1	PubMed
42124356	DERIVED	1	PubMed
39725584	DERIVED	1	PubMed
39229263	DERIVED	1	PubMed

1 to 10 of 21

See all 21 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001350

GET https://conductscience.org/api/diseases/v1/EFO_1001350/drugs?page=2

API reference For AI assistants